Is there targeted therapy for rectal cancer?
Nov 05, 2025
Source: Cainiu Health
Dr. Huang Yuhong
Introduction
Targeted therapy drugs for colorectal cancer primarily act on specific molecular targets of tumor cells. For example, anti-angiogenic agents inhibit the formation of tumor blood vessels, thereby reducing the nutrient supply to tumors; anti-epidermal growth factor receptor agents block signal transduction in tumor cells, suppressing tumor proliferation. These drugs are often used in combination with chemotherapy and can prolong survival in patients with advanced disease.
Generally, targeted therapy is available for colorectal cancer and is more commonly used in the treatment of advanced or metastatic disease. However, the selection of targeted therapy must be based on molecular testing results of the tumor, and it is not suitable for all colorectal cancer patients. If there are related concerns, it is recommended to consult a healthcare provider in advance. Detailed analysis is as follows:
Targeted drugs for colorectal cancer work by acting on specific molecular targets of tumor cells. For example, anti-angiogenic agents inhibit the formation of new blood vessels in tumors, thereby reducing nutrient supply to the tumor; anti-epidermal growth factor receptor (EGFR) agents block signal transduction in tumor cells, suppressing tumor proliferation. These drugs are often used in combination with chemotherapy, which can prolong survival and improve quality of life in patients with advanced disease, especially those who are not candidates for surgical resection or who have recurrent or metastatic disease after surgery.
Not all colorectal cancer patients are eligible for targeted therapy. Prior to treatment, molecular testing must confirm the presence of specific molecular targets in the tumor, such as the status of KRAS, NRAS, and BRAF genes. Targeted drugs are likely to be effective only in patients whose tumors are positive for these targets. In patients with negative targets, targeted therapy may not provide clinical benefit and could increase the risk of adverse effects. Therefore, treatment selection must strictly follow molecular testing results.
Before initiating targeted therapy, appropriate molecular tests should be completed to determine whether the patient meets the criteria for treatment. During therapy, regular follow-up evaluations are necessary to monitor treatment efficacy and adverse reactions. If side effects such as rash or diarrhea occur, patients should promptly inform their doctor so that the treatment regimen can be adjusted accordingly.
